Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.

摘要: Calcineurin inhibitors potentially contribute to risk of cardiovascular events through the development new-onset diabetes mellitus, hypertension and hyperlipidemia. The exact extent which calcineurin affect these factors is difficult establish since pre-existing renal disease concomitant immunosuppressive agents (such as steroids or TOR inhibitors) also exert an effect. Clinical trials have consistently shown a higher incidence mellitus with tacrolimus, has been borne out in large-scale registry analyses. However, approximately 5% cyclosporine than Statin therapy effective treating dyslipidemia significant benefits transplant patients. An individualized approach choice inhibitor, by tacrolimus are selected based on patient's particular profile, may thus help reduce toll mortality among recipients future.